FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005944635> ?p ?o ?g. }

• W2005944635 endingPage "180" @default.
• W2005944635 startingPage "175" @default.
• W2005944635 abstract "Background This randomized study examined the efficacy and safety of levocetirizine in pediatric patients with perennial allergic rhinitis. Health-related quality of life (HRQL) was also investigated, which is particularly relevant in children because of the effects of rhinitis on learning, social activities, and comorbidity. Objective To evaluate the effect of levocetirizine on the Total 4 Symptoms Score, the 50% response rate, the Pediatric Rhinitis Quality of Life Questionnaire (PRQLQ), and investigators' global evaluation of symptom improvement. Methods Double-blind, placebo-controlled, randomized, multicenter trial of levocetirizine, 5 mg once daily for 4 weeks, in 306 children with perennial allergic rhinitis aged 6 to 12 years. There were 154 children in the levocetirizine arm and 152 in the placebo group who completed daily diary cards, and the PRQLQ and investigators' global evaluations were conducted at 3 visits. Results The levocetirizine group showed a significant improvement in 2-week and 4-week Total 4 Symptoms Score compared with placebo (P = .001 and P = .008, respectively). The 50% response rate for the first 2 weeks was 12.3% for the levocetirizine group compared with 3.9% for the placebo group (P = .01). The investigators' global evaluation also favored levocetirizine, because 57.1% of the children in the levocetirizine group were considered markedly or moderately improved compared with 44.7% in the placebo group. Levocetirizine also provided a significantly greater HRQL improvement than placebo at 2 weeks (P = .01), and the frequency of adverse events did not differ significantly from those seen in the placebo group. Conclusion The study confirmed the efficacy of levocetirizine in relieving symptoms of perennial allergic rhinitis in children between 6 and 12 years of age. A HRQL benefit greater than placebo was shown. The treatment was well tolerated. This randomized study examined the efficacy and safety of levocetirizine in pediatric patients with perennial allergic rhinitis. Health-related quality of life (HRQL) was also investigated, which is particularly relevant in children because of the effects of rhinitis on learning, social activities, and comorbidity. To evaluate the effect of levocetirizine on the Total 4 Symptoms Score, the 50% response rate, the Pediatric Rhinitis Quality of Life Questionnaire (PRQLQ), and investigators' global evaluation of symptom improvement. Double-blind, placebo-controlled, randomized, multicenter trial of levocetirizine, 5 mg once daily for 4 weeks, in 306 children with perennial allergic rhinitis aged 6 to 12 years. There were 154 children in the levocetirizine arm and 152 in the placebo group who completed daily diary cards, and the PRQLQ and investigators' global evaluations were conducted at 3 visits. The levocetirizine group showed a significant improvement in 2-week and 4-week Total 4 Symptoms Score compared with placebo (P = .001 and P = .008, respectively). The 50% response rate for the first 2 weeks was 12.3% for the levocetirizine group compared with 3.9% for the placebo group (P = .01). The investigators' global evaluation also favored levocetirizine, because 57.1% of the children in the levocetirizine group were considered markedly or moderately improved compared with 44.7% in the placebo group. Levocetirizine also provided a significantly greater HRQL improvement than placebo at 2 weeks (P = .01), and the frequency of adverse events did not differ significantly from those seen in the placebo group. The study confirmed the efficacy of levocetirizine in relieving symptoms of perennial allergic rhinitis in children between 6 and 12 years of age. A HRQL benefit greater than placebo was shown. The treatment was well tolerated." @default.
• W2005944635 created "2016-06-24" @default.
• W2005944635 creator A5021278395 @default.
• W2005944635 date "2005-08-01" @default.
• W2005944635 modified "2023-09-27" @default.
• W2005944635 title "Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial" @default.
• W2005944635 cites W1481041380 @default.
• W2005944635 cites W1965543955 @default.
• W2005944635 cites W1987477356 @default.
• W2005944635 cites W2005470370 @default.
• W2005944635 cites W2007422312 @default.
• W2005944635 cites W2013370794 @default.
• W2005944635 cites W2030517083 @default.
• W2005944635 cites W2045394909 @default.
• W2005944635 cites W2057541068 @default.
• W2005944635 cites W2061564002 @default.
• W2005944635 cites W2068712706 @default.
• W2005944635 cites W2072295462 @default.
• W2005944635 cites W2077165356 @default.
• W2005944635 cites W2088850334 @default.
• W2005944635 cites W2117257175 @default.
• W2005944635 cites W2153346317 @default.
• W2005944635 cites W2168675538 @default.
• W2005944635 doi "https://doi.org/10.1016/s1081-1206(10)61208-2" @default.
• W2005944635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16136768" @default.
• W2005944635 hasPublicationYear "2005" @default.
• W2005944635 type Work @default.
• W2005944635 sameAs 2005944635 @default.
• W2005944635 citedByCount "69" @default.
• W2005944635 countsByYear W20059446352012 @default.
• W2005944635 countsByYear W20059446352013 @default.
• W2005944635 countsByYear W20059446352014 @default.
• W2005944635 countsByYear W20059446352015 @default.
• W2005944635 countsByYear W20059446352016 @default.
• W2005944635 countsByYear W20059446352017 @default.
• W2005944635 countsByYear W20059446352018 @default.
• W2005944635 countsByYear W20059446352019 @default.
• W2005944635 countsByYear W20059446352020 @default.
• W2005944635 countsByYear W20059446352021 @default.
• W2005944635 countsByYear W20059446352023 @default.
• W2005944635 crossrefType "journal-article" @default.
• W2005944635 hasAuthorship W2005944635A5021278395 @default.
• W2005944635 hasConcept C126322002 @default.
• W2005944635 hasConcept C142724271 @default.
• W2005944635 hasConcept C159110408 @default.
• W2005944635 hasConcept C168563851 @default.
• W2005944635 hasConcept C1862650 @default.
• W2005944635 hasConcept C197934379 @default.
• W2005944635 hasConcept C202061045 @default.
• W2005944635 hasConcept C204787440 @default.
• W2005944635 hasConcept C27081682 @default.
• W2005944635 hasConcept C2779951463 @default.
• W2005944635 hasConcept C2780920841 @default.
• W2005944635 hasConcept C2991744798 @default.
• W2005944635 hasConcept C535046627 @default.
• W2005944635 hasConcept C71924100 @default.
• W2005944635 hasConcept C98274493 @default.
• W2005944635 hasConceptScore W2005944635C126322002 @default.
• W2005944635 hasConceptScore W2005944635C142724271 @default.
• W2005944635 hasConceptScore W2005944635C159110408 @default.
• W2005944635 hasConceptScore W2005944635C168563851 @default.
• W2005944635 hasConceptScore W2005944635C1862650 @default.
• W2005944635 hasConceptScore W2005944635C197934379 @default.
• W2005944635 hasConceptScore W2005944635C202061045 @default.
• W2005944635 hasConceptScore W2005944635C204787440 @default.
• W2005944635 hasConceptScore W2005944635C27081682 @default.
• W2005944635 hasConceptScore W2005944635C2779951463 @default.
• W2005944635 hasConceptScore W2005944635C2780920841 @default.
• W2005944635 hasConceptScore W2005944635C2991744798 @default.
• W2005944635 hasConceptScore W2005944635C535046627 @default.
• W2005944635 hasConceptScore W2005944635C71924100 @default.
• W2005944635 hasConceptScore W2005944635C98274493 @default.
• W2005944635 hasIssue "2" @default.
• W2005944635 hasLocation W20059446351 @default.
• W2005944635 hasLocation W20059446352 @default.
• W2005944635 hasOpenAccess W2005944635 @default.
• W2005944635 hasPrimaryLocation W20059446351 @default.
• W2005944635 hasRelatedWork W2005944635 @default.
• W2005944635 hasRelatedWork W2085830368 @default.
• W2005944635 hasRelatedWork W2154556361 @default.
• W2005944635 hasRelatedWork W2925001634 @default.
• W2005944635 hasRelatedWork W3005722021 @default.
• W2005944635 hasRelatedWork W3012797690 @default.
• W2005944635 hasRelatedWork W3131012514 @default.
• W2005944635 hasRelatedWork W3175465880 @default.
• W2005944635 hasRelatedWork W4283171304 @default.
• W2005944635 hasRelatedWork W4295873639 @default.
• W2005944635 hasVolume "95" @default.
• W2005944635 isParatext "false" @default.
• W2005944635 isRetracted "false" @default.
• W2005944635 magId "2005944635" @default.
• W2005944635 workType "article" @default.